Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial

INTRODUCTION: Patients with triple-class exposed relapsed/refractory multiple myeloma (RRMM) have poor outcomes with substantial healthcare costs. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell therapy, showed deep, durable respon...

Descripción completa

Detalles Bibliográficos
Autores principales: McGarvey, November, Ung, Brian, Carattini, Thomas, Imanak, Ken, Lee, Abraham, Campbell, Timothy B., Patwardhan, Pallavi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499666/
https://www.ncbi.nlm.nih.gov/pubmed/37597153
http://dx.doi.org/10.1007/s12325-023-02623-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499666/
https://www.ncbi.nlm.nih.gov/pubmed/37597153
http://dx.doi.org/10.1007/s12325-023-02623-w

Ejemplares similares